{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:10:10Z","timestamp":1778202610362,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,7]],"date-time":"2027-05-07T00:00:00Z","timestamp":1809648000000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.urolonc.2026.111087","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:32:31Z","timestamp":1775129551000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adequate Bacillus Calmette\u2013Gu\u00e9rin maintenance therapy improves recurrence-free survival in high-risk non\u2013muscle-invasive bladder cancer: A conditional survival study"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-1216","authenticated-orcid":false,"given":"Yukari","family":"Bando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Teishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisuke","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyoshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2026.111087_bib0001","doi-asserted-by":"crossref","first-page":"7655","DOI":"10.1038\/s41598-025-92033-5","article-title":"Trends in the global, regional, and national burden of bladder cancer from 1990 to 2021: an observational study from the global burden of disease study 2021","volume":"15","author":"Su","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2026.111087_bib0002","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2022.12.009","article-title":"Natural history of multiple recurrences in intermediate-risk non-muscle invasive bladder cancer: lessons from a prospective cohort","volume":"173","author":"Sharma","year":"2023","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111087_bib0003","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111087_bib0004","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European association of Urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)\u2014A summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111087_bib0005","unstructured":"National Comprehensive Cancer Network. Bladder cancer (version 1.2025). 2025. Retrieved from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf. Accessed June 19, 2025."},{"key":"10.1016\/j.urolonc.2026.111087_bib0006","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.urology.2020.07.023","article-title":"Increased Bacillus Calmette-Gu\u00e9rin treatment intensity associated with improved outcomes in elderly patients with non\u2013muscle-invasive bladder cancer in United States clinical practice","volume":"145","author":"Richards","year":"2020","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111087_bib0007","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1442-2042.2010.02584.x","article-title":"Maintenance intravesical bacillus Calmette-Gu\u00e9rin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group","volume":"17","author":"Koga","year":"2010","journal-title":"Int J Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111087_bib0008","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/iju.13167","article-title":"Insignificant role of bacillus Calmette-Gu\u00e9rin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: results from a randomized trial","volume":"23","author":"Nakai","year":"2016","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111087_bib0009","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","article-title":"Maintenance therapy with 3-monthly BCG for 3 years is not superior to standard induction therapy in high-risk NMIBC","volume":"68","author":"Martinez-Pineiro","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111087_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111087_bib0011","first-page":"360","article-title":"Single course of intravesical Bacillus Calmette\u2013Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer","volume":"12","author":"Mohamed","year":"2021","journal-title":"Urol Ann"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111087_bib0012","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","article-title":"Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumours in patients with non-muscle-invasive bladder cancer","volume":"108","author":"Hinotsu","year":"2011","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111087_bib0013","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group randomized study of maintenance Bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111087_bib0014","article-title":"Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): systematic review and network meta-analysis according to EAU COVID-19 recommendations","volume":"17","author":"Moon","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111087_bib0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.urols.2014.07.002","article-title":"Maintenance bacillus Calmette\u2013Gu\u00e9rin therapy prolongs recurrence-free survival in non-muscle-invasive bladder cancer: a real-world experience","volume":"26","author":"Liu","year":"2015","journal-title":"Urol Sci"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111087_bib0016","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000020170","article-title":"What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?","volume":"37","author":"Zlotta","year":"2000","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111087_bib0017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.urolonc.2023.10.004","article-title":"Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: the evolving role of PD-(L) 1 inhibition","volume":"41","author":"Bedke","year":"2023","journal-title":"Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:29:02Z","timestamp":1778200142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1078143926000980"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111087","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adequate Bacillus Calmette\u2013Gu\u00e9rin maintenance therapy improves recurrence-free survival in high-risk non\u2013muscle-invasive bladder cancer: A conditional survival study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}